Artivion (NYSE:AORT) Hits New 1-Year High at $26.68

Artivion, Inc. (NYSE:AORT)’s share price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $26.68 and last traded at $26.33, with a volume of 11581 shares traded. The stock had previously closed at $26.00.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Lake Street Capital increased their price target on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Stifel Nicolaus increased their price target on Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Finally, Needham & Company LLC increased their price target on Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th.

Artivion Price Performance

The company has a quick ratio of 4.26, a current ratio of 6.04 and a debt-to-equity ratio of 1.07. The business has a 50-day moving average price of $24.01 and a two-hundred day moving average price of $20.86. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -113.71 and a beta of 1.75.

Artivion (NYSE:AORT) last issued its earnings results on Monday, May 6th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04. Artivion had a positive return on equity of 3.64% and a negative net margin of 2.61%. The company had revenue of $97.43 million for the quarter, compared to analyst estimates of $92.30 million. As a group, research analysts anticipate that Artivion, Inc. will post 0.24 EPS for the current year.

Hedge Funds Weigh In On Artivion

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC raised its position in Artivion by 38.6% in the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after buying an additional 505 shares during the last quarter. Register Financial Advisors LLC purchased a new stake in Artivion in the 1st quarter valued at $114,000. Allspring Global Investments Holdings LLC raised its position in Artivion by 291.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after buying an additional 4,154 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Artivion by 25.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,430 shares of the company’s stock valued at $186,000 after buying an additional 2,108 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Artivion by 7.8% in the 4th quarter. SG Americas Securities LLC now owns 13,393 shares of the company’s stock valued at $239,000 after buying an additional 968 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.